Analyst: Ebola order has positive signal value for Bavarian's investors
![Photo: Sydbank/PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12881097.ece/ALTERNATES/schema-16_9/doc7f8ki6aroth65bqw9k8.jpg)
The new bulk vaccine order placed with Bavarian Nordic for the ebola vaccine to which Johnson & Johnson holds the rights has positive signal value for investors, according to Senior Equity Analyst Søren Løntoft Hansen from the Danish bank Sydbank, following Bavarian Nordic's Tuesday announcement that the order amounted to USD 28m.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic's CBO quits
For subscribers